Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol-electrolyte + simethicone is a combination bowel preparation product used for colon cleansing prior to colonoscopy and other gastrointestinal procedures. The formulation consists of a polyethylene glycol-electrolyte solution (PEG-ELS), which acts as an osmotic laxative by increasing the water content in the intestinal lumen to induce watery diarrhea and empty the colon. The addition of simethicone, an antifoaming agent, reduces the surface tension of gas bubbles in the digestive tract, thereby preventing foam formation. This combination has been shown to significantly improve mucosal visibility and enhance the detection rates of polyps and adenomas during colonoscopy. Clinical studies indicate that the addition of simethicone to PEG-ELS improves the quality of bowel preparation and reduces patient discomfort symptoms, such as general malaise and sleep disturbance, compared to PEG-ELS alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol-electrolyte + simethicone.